新黑色素瘤药物研制成功 针对BRAF基因突变者
时间：2014-07-21 09:09:30 来源：生物探索 点击：
制药巨头罗氏公司最近宣布与Exelixis公司合作开发的治疗黑色素瘤药物组合疗法在临床三期研究中达到其预期终点宣告成功。这也为这一产品最终获得FDA批准扫清了一大障碍。据了解这种疗法是由罗氏公司的Zelboraf和Exelixis公司开发的xobimetinib结合而成，能够针对特定BRAF基因突变患者。使用组合疗法的患者生存期等指标都明显超出了单独使用Zelboraf的患者。罗氏公司表示公司计划在未来几天内将这次临床三期研究的细节公布出来，并将这种组合疗法的上市计划提上日程。而Exelixis公司则获得了丰厚的里程碑奖金。
详细英文报道：
Roche ($RHHBY) and biotech partner Exelixis ($EXEL) said their melanoma-fighting combination therapy met its primary endpoint in Phase III, clearing the way for an FDA application and giving the latter company a boost in its share value.
In a study on 495 patients with a certain mutation of the BRAF gene, a combination of the Exelixis-discovered cobimetinib and Roche's on-the-market Zelboraf helped subjects live significantly longer without disease progression than those treated with Zelboraf alone. The study, called coBRIM, hit its primary goal of progression-free survival, all with a safety profile in keeping with previous studies of the combination, Roche said.
The partners are disclosing only top-line results for now, planning to divulge full details at a future scientific meeting. In the meantime, Roche said it now has the data it needs to support an application with the FDA and other global regulators, though the company has yet to specify a timeline for submissions.
"Despite great progress in our understanding and therapy in recent years, advanced melanoma remains a difficult and deadly disease that requires more treatment options," Chief Medical Officer Dr. Sandra Horning said in a statement. "These encouraging data support the potential combined use of cobimetinib with Zelboraf to block tumor growth longer than Zelboraf alone. We hope this combination therapy will lead to a new option for patients."
As for Exelixis, the Phase III success sent the biotech's shares up about 11% in premarket trading on Monday. And the South San Francisco-headquartered company is expecting three more late-stage data readouts this year, CEO Michael Morrissey said, with results due on studies of the proprietary cabozantinib on prostate, thyroid and renal cancers.
Exelixis discovered cobimetinib in-house and advanced it to the IND stage before signing a deal with Roche's Genentech, reaping $40 million up front with the chance to pocket more milestones down the line. The drug, which targets BRAF V600 mutation-positive melanoma, works by shutting down the kinase MEK, a pathway that regulates growth factor receptors and plays a hand in helping tumors proliferate.
